Clinical Trials Logo

Clinical Trial Summary

This study was run to determine the safety, tolerance, and efficacy of multiple doses of larazotide acetate in subjects with celiac disease following a gluten challenge.


Clinical Trial Description

CLIN1001-004 was a randomized, double-blind, placebo controlled, dose-ranging, 7-arm, multicenter study with a gluten challenge. The objects were multiple dose safety and tolerance; efficacy (intestinal permeability [change in urinary LAMA ratio] and disease signs and symptoms) following gluten challenge.

Following a 21-day screening period, subjects were randomized to one of seven treatments groups: four groups received larazotide acetate (0.25 mg, 1 mg, 4 mg or 8 mg TID) along with an 800 mg gluten challenge, one group received placebo with an 800 mg gluten challenge, a safety control arm received the highest dose of larazotide acetate (8 mg TID) and gluten placebo and the last group received drug placebo and gluten placebo. The gluten challenge was administered as capsules (800 mg TID) with each main meal for a total of 2.4 g daily. Drug or drug placebo was administered TID 15 minutes prior to each main meal. Subjects received their assigned treatments for two weeks (Day 0 through Day 14) and came to clinic for a follow-up visit one week later (Day 21). Subjects remained on their gluten-free diet for the duration of the study. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT00362856
Study type Interventional
Source Innovate Biopharmaceuticals
Contact
Status Completed
Phase Phase 2
Start date September 13, 2006
Completion date March 6, 2007

See also
  Status Clinical Trial Phase
Active, not recruiting NCT02754609 - Hookworm Therapy for Coeliac Disease Phase 1
Terminated NCT01902368 - Celiac Disease Screening N/A
Completed NCT02472704 - Lymphocytic Enteritis and Suspected Coeliac Disease: Gluten vs Placebo N/A
Completed NCT02312349 - Assessment of Gluten-Free Availability in Elaborated Food Stores in Three Neighbourhoods of Buenos Aires City N/A
Recruiting NCT01172665 - Celiac Disease Database N/A
Completed NCT01100099 - HLA-DQ2-gliadin Tetramer for Diagnosis of Celiac Disease Phase 2/Phase 3
Completed NCT00639444 - Risk of Celiac Disease and Age at Gluten Introduction N/A
Not yet recruiting NCT03569007 - Study to Evaluate the Efficacy and Safety of Larazotide Acetate for the Treatment of Celiac Disease Phase 3
Completed NCT02244047 - Cytokine Profile in Children With Celiac Disease Phase 1/Phase 2
Active, not recruiting NCT01695681 - Screen-detected Coeliac Disease, a Population Based Study N/A
Active, not recruiting NCT00617838 - Celiac Disease Prevention N/A
Completed NCT00671138 - Inoculating Celiac Disease Patients With the Human Hookworm Necator Americanus: Evaluating Immunity and Gluten-sensitivity Phase 2
Completed NCT00540657 - A Phase II Study of CCX282-B in Patients With Celiac Disease Phase 2
Completed NCT01137955 - Rifaximin for the Treatment of Persistent Symptoms in Patients With Celiac Disease N/A
Recruiting NCT03288831 - Changes in Intestinal Permeability 4 Hours After Gluten Challenge N/A
Not yet recruiting NCT03678935 - Effect of FODMAP Restriction on Persistent GI-symptoms in Coeliac Patients N/A
Completed NCT01396213 - A Double-blind Placebo-controlled Study to Evaluate Larazotide Acetate for the Treatment of Celiac Disease Phase 2
Recruiting NCT03136731 - Evidence-based Screening Strategies for Celiac Disease N/A
Completed NCT00386165 - Safety Study of Larazotide Acetate to Treat Celiac Disease. Phase 1
Recruiting NCT03351972 - Differences in Preparation for Small Bowel Capsule Endoscopy Phase 4